17:51 EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg says
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Meta Platforms, CVS Health upgraded: Wall Street’s top analyst calls
- Wells downgrades Vertex to Equal Weight on lack of catalysts
- Vertex downgraded to Equal Weight from Overweight at Wells Fargo
- Vertex Pharmaceuticals price target lowered to $533 from $535 at Piper Sandler
- Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley